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A growing number of studies suggested that pancreatic carcinoma
(PC) seems to be the result of a series of genetic alterations,
including the oncogenes and tumour suppressor genes. The prod-
ucts of p53 and Bcl-2 genes are important factors associated with
apoptosis and mechanisms underlying the malignant development
and progression of some human tumours. The mutation of p53
gene and overexpression of its product in PC, including cell lines
and primary human resected tissues, have been extensively studied
(Barton et al, 1991; Aizawa et al, 1996; Lundin et al, 1996;
Ruggeri et al, 1997) but the molecular pathogenesis of Bcl-2
protein during the progression of this malignancy has not been
well-characterized. In the only study published on this, Sinicrope
et al (1996) reported Bcl-2 expression in 45.0% of PC. However,
this result was obtained based on a limited number of samples
including some ampullary adenocarcinomas. In the present study,
we investigated Bcl-2 expression in a larger series to further eval-
uate the status of Bcl-2 expression, its correlation with the altered
p53 protein, and impact on the progression of PC.
MATERIALS AND METHODS
Patients and tissues
Fifty-two patients with a final pathological diagnosis of primary
pancreatic ductal adenocarcinoma and complete clinicopatho-
logical data were enrolled in this study. Cystadenocarcinoma and
adenosquamous carcinoma of the pancreas were excluded.
Histological grading and clinical staging were determined using
criteria described in detail previously (Hermreck et al, 1974;
Klöppel et al, 1985). Most tissues of PC were primary lesions
(n = 30) and some were metastatic lesions (n = 22, including four
liver tissues, and 18 regional or distant lymph nodes), all of which
were obtained at Changhai Hospital, Second Military Medical
University in Shanghai, China, and the Cancer Research Institute
Hospital, Kanazawa University in Kanazawa, Japan. Twenty-eight
patients had complete follow-up records. In addition, six normal
tissues of the pancreas were included in this study as control.
IMMUNOHISTOCHEMICAL PROCEDURES
All specimens were fixed in 10% formalin and embedded in
paraffin and cut into 4-mm-thick serial sections. A highly sensitive
immunohistochemical staining was based on labelled strept-
avidin–biotin complex (SLAB; Dako, Carpinteria, CA, USA) and
combined with the antigen retrieval method by microwave
heating. In brief, after deparaffinization, the sections were treated
for 20 min at 95°C using a microwave in 10 mM sodium citrate for
Bcl-2 staining, and then incubated with blocking serum containing
carrier protein and 15 mM sodium azide at room temperature for
20 min to block non-specific binding. Next, the sections were
incubated at 4°C overnight with primary monoclonal antibody,
anti-Bcl-2 (Clone 124; Dako, Glostrup, Denmark) diluted with
1/60, and then subjected to sequential 20-min incubation at room
temperature with biotinylated link antibody peroxidase-labelled
streptavidin. Staining was detected with AEC Substrate-
Chromogen (Dako, Carpinteria, CA, USA) and the sections then
counter-stained in haematoxylin and mounted using an aqueous
medium. Negative control was performed by replacing primary
antibody using phosphate-buffered saline (PBS). Lymphocytes in
primary sites or tissues of metastatic PC served as an internal
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Summary p53 and Bcl-2 are two important factors related to apoptosis and tumorigenesis. In this study, a series of 52 cases of pancreatic
carcinoma (PC) were investigated using an immunohistochemical assay to determine whether altered expression of Bcl-2 and p53 has an
impact on the progression of this malignancy. Cytoplasmic immunoreactivity for Bcl-2 and nuclear staining of p53 was found in 12 (23.1%)
and 32 (63.5%) cases of PC respectively. Furthermore, an inverse correlation between the expression of p53 and Bcl-2 existed in this series
(P < 0.01). In a subgroup, the proportion of tumours showing that p53-positive and Bcl-2-negative staining was increased with increasing
histological grade and clinical stage (P < 0.05), and moreover, the survival period of those patients whose tumour had this staining was
shorter than those with other staining patterns of combined p53 and Bcl-2 (P < 0.05). Therefore, it is concluded that simultaneously aberrant
expression of Bcl-2 and p53 may confer PC with more malignant clinicopathological characteristics.
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Table 1 Distribution of the four patterns of the expression of Bcl-2 and altered p53 proteins in PC
Clinicopathological No. of
Expression pattern
factors samples p53+/Bcl-2– p53+/Bcl-2+ p53–/Bcl-2– p53–/Bcl-2+
Histological grade
G1 15 4 (26.7) 4 (26.7) 4 (26.7) 3 (20.0)
G2 21 10 (47.6) 1 (4.8) 9 (42.9) 1 (4.8)
G3 16 11 (68.8) 2 (12.5) 2 (12.5) 1 (6.3)
Clinical stage
I 4 1 (25.0) 0 (0) 2 (50.0) 1 (25.0)
II 16 6 (37.5) 5 (31.3) 3 (18.8) 2 (12.5)
III 15 8 (53.3) 1 (6.7) 5 (33.3) 1 (6.7)
IV 17 10 (58.8) 1 (5.9) 5 (29.4) 1 (5.9)
AB
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Figure 1 (A) As an internal positive control, lymphocytes in metastatic sites of pancreatic adenocarcinoma are positive for Bcl-2-staining (´ 200).
(B) Expression of Bcl-2 in normal pancreas: the cytoplasm of acinar cells is partially stained (´ 200). (C) Positive staining of Bcl-2 in a case of
well-differentiated adenocarcinoma of the pancreas (´ 200). Note Bcl-2 staining of lymphocytes in the stroma is also observed. (D) Strong nuclear staining
of altered p53 protein is seen in almost all cancer cells (´ 200)positive control for tumour tissues examined and external positive
control for normal tissues of the pancreas without lymphocytes
respectively. Staining procedures for the altered p53 protein were
similar to those for Bcl-2 except that sodium citrate was replaced
by Target Retrieval Solution (Dako, Carpinteria, CA, USA) in
microwave treatment and diaminobenzidine (Sigma Chemical Co.,
St Louis, MO, USA) used as substrate for colouration. The
primary antibody against the mutant p53 protein (DO7; Dako,
Carpinteria, CA) was used at a dilution of 1:50. A case of colon
adenocarcinoma, which was positive for p53 staining, was used as
a positive control.
Staining results of Bcl-2 protein were judged according to the
method established by Tron et al (1995) and the cytoplasmic
staining of more than 5% of target cells was defined as positive.
Nuclear staining of more than 25% of target cells was taken as the
cut-off value for distinguishing positive from negative expression
of altered p53 protein and the aim of this immunostaining classifi-
cation was to indicate the presence of an underlying gene mutation
(Cordon-Cardo et al, 1994).
Statistical analyses
The c2 test and McNemar’s test were used to analyze the associa-
tion between different variables. The survival analysis was deter-
mined according to the Kaplan–Meier method, and the statistical
significance of the difference in survival distribution was
evaluated by the log-rank test. A P-value of less than 0.05
was considered statistically significant.
RESULTS
Bcl-2 expression in PC
Positive immunoreactivity for Bcl-2 protein was detectable in the
cytoplasm and also frequently on the nuclear membrane (Figure
1A). Bcl-2 expression was found in all six cases of normal
pancreas, but the staining intensity was different among three kinds
of cells of the pancreas: strong, in acinar cells (Figure 1B);
moderate, in islet of Langerhans; and weak, in ductal epithelium.
The staining pattern of Bcl-2 protein was variable among PC
tissues. Some sections showed labelling of the vast majority of
cells, whereas in others only a small area was focused to be positive
for the Bcl-2 protein. In some of the positive sections of PC, focal
and weak staining with strong staining in infiltrating lymphocyte
was a striking feature. Twelve (23.1%) of 52 cases of PC expressed
Bcl-2 protein (Figure 1C) and distributed in seven of 15 (46.7%)
well-differentiated tumours (G1), two of 21 (9.5%) moderately
differentiated (G2) and three of 16 (18.8%) poorly differentiated
tumours (G3) as well as in 25.0% of clinical stage I, 68.9% of stage
II, 13.3% of stage III and 11.8% of stage IV. Statistical analysis
showed that positive staining for Bcl-2 was associated with tumour
pathological grade (G1 vs G2 and G3; P < 0.05) and clinical stage
(stage I and stage II vs stage III and IV; P < 0.05). Additionally, in
28 patients with follow-up records, eight cases had tumours that
were positive and 20 cases that were negative for Bcl-2 staining.
All but one (87.5%) Bcl-2-positive patients, but only nine in 20
(45.0%) patients with Bcl-2 negative staining, survived for 6
months or more after the operation, and a significant difference was
observed between these two groups (P < 0.05, Figure 2).
Expression of altered p53 protein in PC
Normal pancreas did not express the altered or mutant p53 protein.
Unlike Bcl-2, p53-positive staining was more diffuse and intense.
Thirty-two (61.5%) of PC showed nuclear p53-positive staining in
more than 25% of tumour cells stained, among which 20 cases had
strong and diffuse staining in more than 50% of cells (Figure 1D).
Tumours with p53-positive staining distributed in 53.3% (8/15) of
G1, 52.4% (11/21) of G2 and 81.3% (13/16) of G3, and positive
rate of p53 staining in clinical stage I, II, III and IV was 25.0%
(1/4), 68.8% (11/16), 60.0% (9/15) and 64.7% (11/17) respec-
tively. However, p53 immunostaining did not correlate with
tumour pathological grade, clinical stage and prognosis (P > 0.05).
Relation of Bcl-2 expression to altered p53 in PC
Twenty-five (78.1%) of 32 tumours with p53-positive staining did
not express Bcl-2. In addition, among 40 tumours with Bcl-2-
negative staining, 25 cases (62.5%) expressed the altered p53
protein. There was a significantly inverse correlation between the
expression of Bcl-2 and p53 (P < 0.01). Tumours examined,
according to different combinations expressing these two proteins,
were classified into the following four subgroups, i.e. p53+/
Bcl-2– (n = 25), p53+/Bcl-2+ (n = 7), p53–/Bcl-2– (n = 15) and
Bcl-2 expression in pancreatic carcinoma 1077
British Journal of Cancer (1999) 80(7), 1075–1079 © 1999 Cancer Research Campaign 
1
0.8
0.6
0.4
0.2
0
0 2.5 5 7.5 10 12.5 15 17.5 20
Time (months)
S
u
r
v
i
v
a
l
 
r
a
t
e
 
(
%
)
Figure 2 Survival curve in patients with PC according to positive (n n) and
negative (l l) staining for Bcl-2 protein
Figure 3 Survival curve in patients with PC according to the expression of
Bcl-2–/p53+ (l l) and of Bcl-2–/p53+, Bcl-2+/p53+, Bcl-2–/p53–(n n)
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)p53–/Bcl-2+ (n = 5). A trend toward rate increasing with increase
of histological grade and clinical stage was found in the subgroup
of p53+/Bcl-2– staining (Table 1). Additionally, among 28 patients
with follow-up records, 12 demonstrated Bcl-2–/p53+ and 16
demonstrated three other patterns. Only three cases (25.0%) in the
former subgroup, but ten of the other cases (62.5%), survived
more than 6 months after the operation. Furthermore, statistical
analysis showed that patients with p53+/Bcl-2– had a greater
number of worse prognoses than those with the other three expres-
sion patterns of these two proteins (P < 0.05, Figure 3).
DISCUSSION
In this study, we took into account the expression of Bcl-2 and its
relation to the altered p53 protein in PC. Based on these results,
we evaluated the impact of the altered expression of these two
proteins on the progression of PC. Bcl-2 was expressed in normal
pancreatic tissue examined, which is consistent with previous
findings (Krajewski et al, 1994; Sinicrope et al, 1996).
Interestingly, we also observed the presence of Bcl-2 expression in
normal duodenal epithelial cells and hepatocytes adjacent to
metastatic PC tissues. Actually, some studies have demonstrated
that Bcl-2 expression in other human normal tissues is not
uncommon (McDonnell et al, 1992; Yan et al, 1996).
The impact of Bcl-2 expression on the progression of PC has
not been well-characterized. Sinicrope et al (1996) found that
about 45.0% of PC expressed Bcl-2 protein, which is higher than
that of our study. It is likely that case selection is responsible for
this discrepancy, as all cases of PCs examined in the study of
Sinicrope et al (1996) were resectable. The mutually exclusive
expression of Bcl-2 and altered p53 protein shown in PC, in fact,
also existed in the normal tissue of the pancreas. Our results
showed that all normal tissues of the pancreas did not express the
altered p53 but all cases expressed Bcl-2. Recently, a similarly
inverse relation has been observed in other human cancers,
including gastric lymphoma (Nakamura et al, 1996), lung cancer
(Ishida et al, 1997) and breast carcinoma (Hurlimann et al, 1995).
Our results and those described above, however, seem paradoxical
given the known functions of Bcl-2 as an oncoprotein. Actually,
the mechanisms regulating Bcl-2 expression appear to be different
among human tissues and, furthermore, role of Bcl-2 could not
fully be explained by its function of oncoprotein. The mutually
exclusive expression of Bcl-2 and p53 shown in the present study
raises a possibility that Bcl-2 protein could be down-regulated by
the mutant protein. Similarly, Haldar et al (1994) reported that
mutant p53 protein might down-regulate Bcl-2 in breast cancer
cell, and Miyashita et al (1994) confirmed this using Bcl-2/CAT
receptor gene plasmid and co-transfection assay. In a study of
breast cancer done by Krajewski et al (1997), the percentage of
Bcl-2-immunopositive tumour cells was found significantly lower
in the p53-positive (median 20%) subset as compared to the p53-
negative (median 85%) subsets. Concomitantly, we observed that
altered p53 protein was expressed diffusely but Bcl-2 expression
remained weak in some sections of PC. There have been some
studies suggesting that the decreased expression of Bcl-2 confers
more malignant biological behaviour and clinicopathological
features on some types of tumour (Tron et al, 1995; Stattin et al,
1996; Ohbu et al, 1997; Tjalma et al, 1997). Furthermore, such
role of Bcl-2 protein seems to be enhanced in the presence of the
altered p53 protein. In the present study, we found that the absence
of Bcl-2 expression was mainly observed in the population of
highly malignant tumours (81% of G3 and 88% of clinical stage
III and IV), moreover, most of which expressed altered p53
protein. Additionally, the finding of a strong association between
simultaneously altered expression of these two proteins and poor
prognosis in some patients with PC was consistent with the litera-
ture, suggesting that the expression of p53+/Bcl-2– has a bad
impact on patient prognosis in at least some tumours (Pezzella et
al, 1993; Haldar et al, 1994; Piris et al, 1994).
Bcl-2 has been considered to have function of blocking apop-
tosis or programmed cell death. However, the mechanisms under-
lying apoptosis are very complicated, some of which at the present
are still unclear. Shiraki et al (1997) reported that liver metastasis
of colon carcinoma was correlated with apoptosis, suggesting that
programmed cell death might promote metastasis. We noticed that
Bcl-2 antibody rarely stained tumour tissues in metastatic liver of
PC, but normal hepatocytes and lymphocytes adjacent to cancer
nest could be readily stained. Furthermore, among 17 tumour
tissues with clinical stage IV in this series, all of which had liver or
distant lymph node metastases, 15 (88.2%) cases did not express
Bcl-2, suggesting that the absence of Bcl-2 expression was related
to tumour metastasis. On the basis of these findings, it may be
speculated that the altered expression of Bcl-2 and p53 during
the development and progression of human PC is correlated to
apoptosis to some extent, although the mechanism of apoptosis
involved with the promotion of metastasis is unknown.
In accordance with the absence of Bcl-2 protein, the mutant p53
was reported to be involved in neovascularization or angiogenesis,
tumour invasion and metastasis (Dameron et al, 1994; Kieser et al,
1994; Fontanini et al, 1997). Moreover, Yamanaka et al (1993)
reported elevated messenger RNA and protein levels for acid fibro-
blast growth factor and basic fibroblast growth factor, two angio-
genetic factors, in most PC tissues examined. Therefore, it is possible
that the simultaneously altered expression involving Bcl-2 and p53
confers more malignant clinicopathological characteristics, including
prognosis on some tumours (Piris et al, 1994; Hurlimann et al, 1995;
Tjalma et al, 1997). On the other hand, we used not only primary
tumours of PC but also metastases for analysis. Since it is known that
metastases originate from a subgroup of cells, the expression of prog-
nostic factors might be different in metastases than in the primary
tumours. However, it seems possible that the specialized subpopula-
tions of cells producing metastases pre-exist in heterogeneous cells
of primary tumour, and they represent at least some characters of
primary tumour.
Our study is only preliminary and neither of the explanations
described above for simultaneously aberrant expression of Bcl-2
and p53 in PC is satisfying. Further correlative investigations on
p53, Bcl-2 and another member of Bcl-2 family, especially on
dynamic links among them, will provide useful information about
the molecular complexity of genetic diagnosis or control of PC,
one of the most malignant of all diseases.
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